What We're Reading: HPV Vaccine Use; $4 Million Drug; ACS Fundraising Concerns

Article

A report from the President’s Cancer Panel has found that use of human papillomavirus (HPV) vaccines remain low, despite improvements; Novartis believes that its new gene therapy to treat spinal muscular atrophy could cost $4 million to $5 million per patient; the chief medical officer at the American Cancer Society (ACS) resigned over concerns regarding controversial fundraising partnerships.

Use of HPV Vaccines Remain Low

A report from the President’s Cancer Panel has found that use of human papillomavirus (HPV) vaccines remain low, despite improvements. Less than half of boys and girls in the Unites States are vaccinated against preventable cancers. Progress on HPV vaccine uptake has only been around 5% per year. However, meeting the 2020 target is still possible, and the report identifies 4 strategies that can overcome barriers to uptake.

A Gene Therapy That Could Cost $4 Million

Novartis believes that its new gene therapy to treat spinal muscular atrophy could cost $4 million to $5 million per patient. According to Reuters, the drug maker believes that the astronomical price tag would still be cost effective for health systems for the 1-time drug to treat a deadly disease. Spinal muscular atrophy is a rare genetic disorder and the treatment, AVXS-101, demonstrated 100% survival rate after 24 months, STAT reported.

ACS Fundraising Partnerships Raise Concerns

The chief medical officer at the American Cancer Society (ACS) resigned over concerns regarding controversial fundraising partnerships, such as with supplements company, Herbalife International. The New York Times reported that Otis W. Brawley, MD, MACP, FASCO, FACE, had been uncomfortable with the society receiving donations from “businesses with questionable health credentials.” Other unusual partnerships include those with Long John Silver’s, the seafood chain, and Tilted Kilt, a sports pub.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.